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Two growth inhibitory hurdles that must be overcome by the evolving cancer cell include pathways regulated by RB
and p53. In human melanoma cells, inactivation of a single locus, CDKN2A, can lead to abrogation of both RB and
p53 functionality through loss of the two CDKN2A cognate transcripts—p16 and p14ARF, respectively. We thus set
out to assess how recurrent patterns of genetic injury at three critical human melanoma loci—CDKN2A, TP53, and
CDK4—cooperate to disrupt both RB and p53 pathways. Overall, 77.8% of the melanoma cell lines analyzed showed
genetic evidence of dual RB and p53 pathway compromise; this percentage is even higher if protein expression
loss is considered. Although homozygous deletion of all three critical CDKN2A exons (exons 1b, 1a, and 2) rep-
resent the most common mechanism, concurrent loss of CDKN2AExon1a and CDKN2AExon1b and simultaneous point
mutagenesis of CDK4 and TP53 reﬂect alternative cassettes of dual inactivation. In cell lines with isolated
CDKN2AExon2 mutations, coincident alterations in TP53 or deletion of CDKN2AExon1b suggest that p16 transcript
may be preferentially targeted over the p14ARF transcript as additional p53 pathway lesions are recruited. More-
over, predictive modeling of CDKN2AExon2 missense mutations further suggests that the amino acid substitutions
in this region negatively impact p16 to a greater extent than p14ARF. Taken together, our data point to a clear need
in human melanoma cell lines, as in its murine counterpart, to disrupt both RB and p53 pathways and recurrent
mechanisms may play into the unique genetic vulnerabilities of this tumor type.
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Negotiating the cell cycle checkpoints imposed by the RB
and p53 pathways is an essential rite of passage for most
aspiring cancer cells. In melanoma, this is frequently
achieved through genetic injury of the CDKN2A locus. Inac-
tivation of this locus is a particularly efficient means of ab-
rogating both RB and p53 pathways as the CDKN2A protein
products, p16 and p14ARF, serve to maintain the functional
activities of RB and p53, respectively (Tsao, 2000).
Although mutational analyses of RB pathway genes have
been reported for human melanoma (Bartkova et al, 1996;
Flores et al, 1996; Maelandsmo et al, 1996; Castellano et al,
1997; Kumar et al, 1999), a concurrent analysis of these
genes along with TP53 has been less forthcoming. In one
collection, Kumar et al (1998a, 2001) found CDKN2A mu-
tations in six of 31 primary melanoma cell lines and a single
TP53 mutation from the same set of specimens; no appar-
ent relationship between the two loci were identified. More
recently, Daniotti et al (2004) examined eight loci (BRAF,
NRAS, HRAS, KRAS, PTEN, CDKN2A, CDK4, and TP53) in
a collection of short-term melanoma cell lines and found
lesions of the CDKN2A locus and mutations of TP53 in 28
and 10 of 41 specimens, respectively. The study, however,
did not specifically address recurrent genetic interactions
between CDKN2A/CDK4 and TP53 mutations. Moreover,
recent animal models of cutaneous melanoma have further
strengthened and defined CDKN2A’s role in melanoma
development.
In mice, spontaneous melanomas have been engineered
with an oncogenic HRAS allele targeted to melanocytes that
constitutively lack components of the CDKN2A (INK4a in
mice) locus (INK4aExon1a, INK4aExon1b; Sharpless et al, 2003
and INK4aDExons2/3; Chin et al, 1997) or deletions of TRP53
(Bardeesy et al, 2001). In genetic analyses, RAS-driven
murine melanomas that develop from INK4aDExons2/3 mice
are typically free of TRP53 mutations (Chin et al, 1997)
whereas melanomas that emerge from TRP53-deficient
mice are usually devoid of p19ARF and p16 defects (Bard-
eesy et al, 2001). But when individual elements of INK4a are
examined, one finds that melanomas generated from INK4-
aExon1a-deleted mice (i.e., p16INK4a specific) exhibit a high
rate of p19ARF loss or TP53 mutations and melanomas in-
duced from INK4aExon1b-deleted mice (i.e., p19ARF specific)
show frequent p16 loss or mutagenesis (Sharpless et al,
2003). These results suggest that, during murine melanoma
tumorigenesis, both RB and p53 functions are frequently
abolished and that recurrent genetic vulnerabilities among
the complex INK4a–CDK4–TRP53 network may exist. In
light of this murine data, which strongly support an essen-
tial role for dual RB and p53 functional loss in melanoma,
we set out to examine the CDKN2A–CDK4–TP53 circuit
in greater detail from a large panel of human melanoma
cell lines and hypothesize that melanoma cells use
certain recurrent mechanisms to disrupt the RB and p53
pathways.
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Results
CDKN2A exon 2 mutations As shown in Table I, 10 of 36
cell lines had isolated mutations (N¼ 9) or homozygous de-
letion (n¼1) of CDKN2A exon 2 (CDKN2AExon2). Seven of
the 10 mutations are deleterious (four nonsense, two frame-
shift, one deletion) and the remaining three are missense
mutations that have been previously reported (Ruas and
Peters, 1998). Five of the nine mutations in CDKN2AExon2
were C(C)4T(T) or G(G)4A(A) changes that are character-
istic of ultraviolet-induced lesions on the coding and non-
coding strands, respectively; thus, it is unlikely that these
mutations spontaneously arose in culture although they may
have experienced positive selection pressure. In four of
these lines, TP53 was also mutated whereas in one line
(A375), CDKN2AExon1b was deleted; therefore, nearly half of
the isolated CDKN2AExon2 alterations were accompanied by
additional p53 pathway disruptions. This raises the possi-
bility that more subtle changes, especially the point muta-
tions, may impact p16 to a greater extent than p14ARF. To
test this hypothesis, we utilized the PolyPhen (http://
www.bork.embl-heidelberg.de/PolyPhen/) program to pre-
dict the functional effects of the identified missense muta-
tions. As nonsense and frameshift mutations are presumed
deleterious and synonymous changes are theoretically si-
lent at the protein level, these variants are not appropriately
modeled with PolyPhen. The PSIC scores for p16 and
p14ARF are listed in Table I for the cell lines; in all predict-
able cases, the anticipated impact of the CDKN2AExon2
mutations are more severe on p16 than p14ARF. As can be
seen in Fig 1, all of the changes in p16, but only four of nine
of the alterations in p14ARF, were predicted to be either
deleterious or ‘‘probably damaging;’’ furthermore, a synon-
ymous change and a benign change were seen only with
p14ARF. Although these results are compatible with a p16-
driven mutagenic program, our own data set represents
only a small number of mutations. We thus set out to anal-
yze a set of 117 CDKN2AExon2 point mutations compiled by
Ruas and Peters (1998).
Table II lists the compiled CDKN2AExon2 point mutations
(Ruas and Peters, 1998), its associated PSIC score, and its
predicted effect on p16 and p14ARF. As shown in Fig 2A,
over 30% of the reported CDKN2AExon2 point mutations
were synonymous in the p14ARF reading frame whereas
another 30% were predicted to be ‘‘benign.’’ In contrast,
50% of these alterations were nonsense or ‘‘probably dam-
aging’’ in the p16 reading frame.
To examine the relative effect of each mutation on the
two proteins specifically, we plotted the ratio of the
p16:p14ARF PSIC scores as a function of the codon
number (in p16 designation; Fig 2B). A ratio o1 suggests
a greater p14ARF impact whereas a ratio 41 suggests a
larger p16 impact. As can be seen, most mutations in
CDKN2AExon2 (45/55) are more damaging to p16 than to
p14ARF. The overall p16/p14ARF ratio is 1.94 (95% CI:
1.34–2.54). Taken together, for isolated CDKN2AExon2 point
mutations, the coincident mutagenesis of p53 pathway
genes and the high frequency of synonymous or benign
p14ARF changes compared with the high frequency of
damaging or deleterious p16 alterations suggest that these
CDKN2AExon2 alterations are preferentially impacting the RB
pathway through p16 inactivation and that additional events
are recruited to compromise p53 function.
Homozygous deletions of CDKN2A exons We used a
multiplex reaction to assay for the presence or absence of
individual CDKN2A exons (Fig 3). Homozygous deletions
CDKN2AExon2 in conjunction with CDKN2AExon1a and/or
CDKN2AExon1b represent the most common mechanism of
RB and p53 pathway disruption in melanoma (Table I). Al-
though deletion of CDKN2AExon2 is an efficient means of
abrogating both RB and p53 functionalities, it is not essen-
tial. Three cell lines exhibited concurrent homozygous de-
letions of CDKN2AExon1a and CDKN2AExon1b without
deletion of CDKN2AExon2. Structurally, this deleted cassette
would also perturb p16 and p14ARF. As expected by its
epistatic relationship, there is also a strong negative asso-
ciation between CDKN2AExon1b loss and TP53 mutations
(p¼0.006, Fisher’s exact test).
CDK4 mutations Four melanoma lines had CDK4 muta-
tions (two CDK4K22Q, one CDK4R24C, one CDK4R24H); three
of these have been previously described (Tsao et al, 1998a).
In one line, WM1205, the normal CDK4 allele has been
shed, a phenomenon that has been described with other
oncogenes in melanoma such as NRAS and BRAF (Tsao
et al, 2004). Unlike CDKN2A disruption, however, CDK4
activation affects only the RB pathway. As such, we also
found genetic evidence of p53 inactivation in all four spec-
imens. In line WM1205, CDKN2A is additionally deleted
whereas in lines SK-Mel 28, SK-Mel 37, and SK-Mel 39,
TP53 is concomitantly mutated. We propose that the
CDKN2A loss, which accompanied the CDK4K22Q muta-
tion, selectively inactivates p14ARF rather than p16 and
conspires to further promote growth. To the best of our
knowledge, this is the first report of the apparent associ-
ation between CDK4 and TP53 mutations in melanoma cell
lines (p¼0.0375, Fisher’s exact test).
Normal CDKN2A/CDK4 In eight cell lines, neither CDKN2A
nor CDK4 were mutated (Table I). We were able to assess
p16 expression in seven of eight lines using the cell line
SK-Mel 28 as a positive control (known CDK4R24C mutant).
In five of seven assayed lines, p16 levels was tremendously
reduced (o15% of control), suggesting that other genetic or
epigenetic mechanisms may be responsible for the loss in
p16 protein expression. In one cell line (MM-LH), p16 levels
were found to be at 55% and 110% of the positive control
on two separate analyses. Interestingly, this cell line was
cultured from a visceral metastasis that recurred 18 y after
the primary melanoma (H. R. Byers, personal communica-
tion), raising the possibility that the p16 expression may
have contributed to its slow progression.
Discussion
Our systematic mutational analysis of the CDKN2A, CDK4,
and TP53, in concert with reported results (Daniotti et al,
2004), suggest that recurrent genetic mechanisms exist to
abrogate both the RB and p53 pathways in high percentage
(approximately 70%) of melanoma cell lines (Fig 4). These
results speak to the importance of cooperativity between
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Table I. Status of melanoma cell lines
Cell lines
TP53
exons 5–9
CDKN2A
exon 1b
CDKN2A
exon 1a CDKN2A exon 2
PSIC
p16/ARF
CDK4
exon 2
Normalized
p16 content
SK-Mel 63 WT WT WT R112P; NCa 2.15/NC WT
HS944T WT WT WT H83Y; A97Va,b 2.67/1.16 WT
MGH ST-1 WT WT WT G89S; G103Ka,b 2.11/1.80 WT
SK-Mel 131 WT WT WT R58-A60del; P72-G73delþG74Ra Frameshift
Swift WT 258C4G
c WT R58X; P72La,b NS/2.55 WT
A375 WT HD WT E61X; G75Va NS/1.69 WT
WM164 Y220Ca WT WT G61fs; R75fsa Frameshift WT
WM1158 P98Ad WT WT R80X/P94La,b NS/2.55 WT
CHL-1 H193Ra WT WT W110X/G125Ra,b NS/1.80 WT
NAE F270Ia,d WT WT HD WT
MGH-BO-1 WT WT HD HD WT
K2 WT WT HD HD WT
MM608 WT HD HD HD WT
SK-Mel 119 WT HD HD HD WT
UACC903 890A4Gc,d HD HD HD WT
MGH-MC-1 WT HD HD HD WT
WM1205 WT HD HD HD K22Qa,e
K4 WT HD HD HD WT
MM455 WT HD HD HD WT
RU WT HD HD HD WT
MGH-QU-1 WT HD HD HD WT
Mel-Juso WT HD HD HD WT
WM115 WT HD HD WT WT
WM239A WT HD HD WT WT
WM35 WT HD HD WT WT
SK-Mel 39 F113Sa WT WT WT K22Qa
SK-Mel 28 L145Ra WT N/A WT R24Ca,b 100f
SK-Mel 37 R175Ha WT WT WT R24Ha,b
MM-LH G244Ra WT WT WT WT 110/55g
K1 R273Ha WT WT WT WT 12
K11 WT WT WT WT WT 7
MGH-TH-1 WT WT WT WT WT 0
K23 WT WT WT WT WT 8
K25 WT WT WT WT N/A 14
K19 WT WT WT WT WT 52
HS939 WT WT WT WT WT N/A
aPreviously reported mutation.
bUV signature: C(C)4T(T) coding strand; G(G)4A(A) non-coding strand.
cSynonymous change.
dWT allele retained.
eWT allele lost.
fDetection of protein by western blot; amount of protein normalized to b-tubulin levels at same amount of loaded protein and gel exposure; relative
amount (%) compared with positive control SK-Mel 28 (CDK4 R24C mutation).
gp16 expression levels on two separate analyses.
p16, ARF amino acid change; NC, no change; N/A, not analyzed; HD, homozygous deletion; NS, nonsense mutation; WT, wild type.
Mutations are identified by shading for quick identification.
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lesions from the two pathways in melanoma pathogenesis
and reinforce the significance of p53 involvement. Six re-
current patterns account for nearly 80% of these dual path-
way injuries.
Homozygous deletion of the three critical CDKN2A ex-
ons—1a, 1b, and 2—represent the most frequent genetic
event in our cell lines. Although models suggest that iso-
lated INK4aExon2 deletion is sufficient to induce murine me-
lanoma (Chin et al, 1997), isolated CDKN2AExon2 deletion is
rare and may not be sufficient in human melanoma. Fur-
thermore, long-term in vitro selection may favor the loss of
additional exons. Alternatively, it is also possible that a co-
operative effect exists whereby partial deletion of CDKN2A
initially may then facilitate subsequent deletion of other
adjoining exons. Partial homozygous deletions of
CDKN2AExon1a/CDKN2AExon2 and CDKN2AExon1a/
CDKN2AExon1b also exist albeit at a lower frequency. Con-
current deletion of CDKN2AExon1a and CDKN2AExon1b as a
cassette occurs about 5% of the cases and is an interesting
mechanism used by the cell to disrupt both p16 and
p14ARF without involving CDKN2AExon2. In mice, loss of
either INK4aExon1a or INK4aExon1b can cooperate with Tyr-
RAS to generate tumors; however, there is frequent cross-
inactivation of the non-targeted pathway (i.e., p53 muta-
tions in INK4aExon1a-derived melanomas and vice versa)
(Sharpless et al, 2003).
Point mutations and microdeletions or microinsertions
within CDKN2AExon2 account for the second most common
class of identifiable lesions. Predictive analyses of our re-
sults and published reports suggest that point mutations
within CDKN2AExon2 preferentially target the p16 transcript
over the p14ARF transcript. This selectivity is by no means
absolute. As there are p14ARF-specific nonsense mutations
that are synonymous in the p16 reading frame and other
mutations that clearly compromise p14ARF function in bi-
ochemical assays (Rizos et al, 2001), select targeting of the
p14ARF transcript can occur; however, these develop less
frequently than the p16 mutations that are synonymous in
the p14ARF reading frame (Table II). Furthermore, on a
whole, CDKN2AExon2 point mutations are more damaging to
p16 than p14ARF by prediction (Fig 3).
For cell lines with retained p16 expression and wild-type
CDKN2A, functional disruption of the RB locus, which was
not examined in our analysis, has been described in a few
melanoma cell lines (Bartkova et al, 1996). In cell lines that
demonstrate loss of p16 expression, CDKN2A promoter
methylation and other upstream and deep intronic muta-
tions may play a role.
Another interesting observation that emerges from our
analysis involves CDK4 and TP53. If the RB pathway is
selectively affected by CDK4 mutagenesis, positive pres-
sure will select for cells with complementary mutations in
TP53. We show, for the first time, a positive association
between CDK4 and TP53 mutations; if we consider the loss
of CDKN2A in cell line WM1205 (CDK4K22Q) as a p14ARF
injury, then all four CDK4-mutant lines (which are RB-path-
way specific) are also accompanied by p53-pathway in-
sults. Of note, the one cell line reported by Daniotti et al
(2004) to contain a K22R mutation (line 4686M) is also ac-
companied by a TP53 mutation.
We also found the strongest negative association be-
tween CDKN2AExon1b deletion (p14ARF loss) and TP53 mu-
tations. This finding strengthens the putative epistatic
relationship between p14ARF and p53 (Pomerantz et al,
1998; Zhang et al, 1998).
Daniotti et al (2004) reported a positive association be-
tween BRAFV600E and p53 mutations. In our own collection,
two of the nine p53 mutant cell lines had both wild-type
BRAF and NRAS (data not shown). This raises the possibility
that the positive association seen between BRAF and TP53
may reflect an underlying negative association between
NRAS, which is epistatic to BRAF, and TP53. A pooled
analysis of data from our cell lines and those reported by
Daniotti et al (2004) shows a statistically significant negative
association between TP53 and NRAS (75 cell lines pooled,
NRAS normal/TP53 normal: 46; NRAS mutant/TP53 normal:
12; NRAS normal/TP53 mutant: 17; NRAS mutant/TP53
mutant: 0; p¼ 0.034, Fisher’s exact test). One possible ex-
planation for this negative association is that NRAS muta-
genesis may be favored in tumors with early CDKN2A
inactivation rather than TP53 inactivation. Along these lines,
Eskandarpour et al (2003) recently reported that 20 of 21
primary melanomas from patients with germline CDKN2A
mutations harbored NRAS mutations compared to one of 10
sporadic primary melanomas (po0.001). In melanoma cell
lines, the combination of NRAS and TP53 mutations appar-
ently do not undergo positive selection; it is possible that the
coincidence of these two mutations are selected against by
an undisclosed mechanism.
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Figure 1
Predicted effects of CDKN2A exon 2 mutations on melanoma cell
lines investigated in study. Using PolyPhen, the predicted effects of
exon 2 mutations on p16 and p14ARF in nine melanoma cell lines are
shown. In the p14ARF reading frame, one point mutation had no effect,
one point mutation had a ‘‘benign effect,’’ three point mutations had a
‘‘possibly damaging’’ effect, two point mutations had a ‘‘probably
damaging’’ effect, and two mutations were deleterious. In the p16
reading frame, three point mutations had a ‘‘probably damaging’’ effect
while six mutations were deleterious.
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Table II. Predicted effects of 117 reported CDKN2A exon 2 point mutations on p16 versus ARF
p16 alteration p16 PSIC score Predicted effect ARF alteration ARF PSIC score Predicted effect
P16 versus
ARF
None Synonymous S73R 0.2 Benign ARF
None Synonymous G75R 1.2 Benign ARF
None Synonymous A79T 1.2 Benign ARF
None Synonymous R82C 0.9 Benign ARF
None Synonymous G83R 0.1 Benign ARF
None Synonymous L104I 0.5 Benign ARF
None Synonymous A117P 1.1 Benign ARF
None Synonymous A121T 1.1 Benign ARF
None Synonymous A128T 0.9 Benign ARF
None Synonymous A128S 0.7 Benign ARF
None Synonymous R99C 1.8 Possibly damaging ARF
None Synonymous R87C 2.3 Probably damaging ARF
None Synonymous P94S 2.1 Probably damaging ARF
None Synonymous R88X Deleterious ARF
None Synonymous P98X Deleterious ARF
A76T 0.094 Benign R90H 1.4 Benign Both
R107C 0.146 Benign A121V 0.0 Benign Both
E69D 0.571 Benign A84P 0.5 Benign Both
H66Y 0.827 Benign P80L 0.6 Benign Both
D108Na 0.96 Benign R122Q 0.9 Benign Both
D84E 0.965 Benign R99S 1.4 Benign Both
E69K 1.204 Benign G83E 1.3 Benign Both
V106M 1.209 Benign R120H 1.1 Benign Both
L62V 1.214 Benign A76G 1.1 Benign Both
D105E 1.214 Benign R120S 1.4 Benign Both
A100V 1.355 Benign R115G 0.2 Benign Both
A100L 1.383 Benign G114A; R115G 1.4 Benign Both
E61D 1.426 Benign A76P 1.2 Benign Both
A100P 1.452 Benign G114A 1.4 Benign Both
A73T 0.205 Benign R87H 1.6 Possibly damaging Both
E88K 0.588 Benign G102E 1.8 Possibly damaging Both
V51I 0.615 Benign G65D 1.8 Possibly damaging Both
M52I 1.703 Benign D67H 1.9 Possibly damaging Both
R99P 1.718 Possibly damaging G114S 1.4 Benign Both
A68T 1.764 Possibly damaging R82Hc 1.5 Benign Both
D84N 1.903 Possibly damaging R98Q 1.4 Benign Both
A68La 1.036 Possibly damaging R82Lb 1.5 Possibly damaging Both
E88D 1.341 Possibly damaging G103W 1.8 Possibly damaging Both
D116N 1.656 Possibly damaging G130E 1.8 Possibly damaging Both
P75S 1.561 Possibly damaging P89L 2.6 Probably damaging Both
D116Y 1.88 Possibly damaging G130V 2.0 Probably damaging Both
R112G 1.987 Possibly damaging P126Rd 2.0 Probably damaging Both
H98Y 2.024 Probably damaging A112V 0.9 Benign Both
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Table II. Continued
p16 alteration p16 PSIC score Predicted effect ARF alteration ARF PSIC score Predicted effect
P16 versus
ARF
D74N 2.08 Probably damaging R88Q 1.3 Benign Both
D92H 2.144 Probably damaging G106A 1.4 Benign Both
P70A 2.17 Probably damaging A84G 1.1 Benign Both
G101Wa 2.291 Probably damaging R115L 0.2 Benign Both
N71Ka 2.306 Probably damaging L86Mc 0.8 Benign Both
N71K 2.306 Probably damaging L86V 1.0 Benign Both
V59Ga 2.52 Probably damaging S73R 0.2 Benign Both
H83Y 2.667 Probably damaging A97V 1.2 Benign Both
P114S 2.731 Probably damaging A128V 0.9 Benign Both
H83N 2.892 Probably damaging A97E 1.4 Benign Both
A60T 0.691 Probably damaging G74D 1.3 Benign Both
A85T 1.892 Probably damaging R99H 1.1 Benign Both
S56Ia 2.01 Probably damaging Q70H 1.7 Possibly damaging Both
G89S 2.112 Probably damaging G103K 1.8 Possibly damaging Both
T93R 2.222 Probably damaging H107Q 1.8 Possibly damaging Both
D108H 2.26 Probably damaging R122P 1.6 Possibly damaging Both
H98P 2.465 Probably damaging P113S 1.8 Possibly damaging Both
M53Va 2.466 Probably damaging D67H 1.9 Possibly damaging Both
M53Ia 2.516 Probably damaging D68H 1.9 Possibly damaging Both
C72G 2.681 Probably damaging L86R 1.7 Possibly damaging Both
D108Y 2.766 Probably damaging R122L 1.6 Possibly damaging Both
M52K 2.936 Probably damaging H66Q 1.9 Possibly damaging Both
A118Ta 1.732 Probably damaging G132D 1.6 Possibly damaging Both
T93A 1.884 Probably damaging H107R 1.8 Possibly damaging Both
D84H 2.19 Probably damaging R98P 2.0 Probably damaging Both
D84Y 2.407 Probably damaging R98L 2.0 Probably damaging Both
E61X Deleterious G75V 1.7 Possibly damaging Both
E69X Deleterious G83V 1.8 Possibly damaging Both
C72X Deleterious R87S 1.8 Possibly damaging Both
W110X Deleterious G125R 1.8 Possibly damaging Both
R58Xa Deleterious P72L 2.6 Probably damaging Both
H66X Deleterious P80L; R81G 2.0 Probably damaging Both
R80X Deleterious P94L 2.6 Probably damaging Both
E88X Deleterious G102V 2.0 Probably damaging Both
V95A 0.115 Benign None Synonymous p16
A57Va 0.276 Benign None Synonymous p16
R99Q 0.306 Benign None Synonymous p16
A76V 0.515 Benign None Synonymous p16
H66R 0.826 Benign None Synonymous p16
G111D 0.928 Benign None Synonymous p16
A73D 0.99 Benign None Synonymous p16
P75L 1.029 Benign None Synonymous p16
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Table II. Continued
p16 alteration p16 PSIC score Predicted effect ARF alteration ARF PSIC score Predicted effect
P16 versus
ARF
V51A 1.077 Benign None Synonymous p16
H98R 1.151 Benign None Synonymous p16
A102V 1.892 Benign None Synonymous p16
R80Q 1.535 Possibly damaging None Synonymous p16
R107H 1.601 Possibly damaging None Synonymous p16
A68V 1.677 Possibly damaging None Synonymous p16
E61G 1.698 Possibly damaging None Synonymous p16
R99Pa 1.718 Possibly damaging None Synonymous p16
E69V 1.767 Possibly damaging None Synonymous p16
L62Pa 1.887 Possibly damaging None Synonymous p16
R80L 0.891 Probably damaging None Synonymous p16
D116V 2.07 Probably damaging None Synonymous p16
N71Sa 2.081 Probably damaging None Synonymous p16
A102E 2.117 Probably damaging None Synonymous p16
R112P 2.148 Probably damaging None Synonymous p16
D116G 2.162 Probably damaging None Synonymous p16
D84V 2.21 Probably damaging None Synonymous p16
L97Ra 2.377 Probably damaging None Synonymous p16
C72Y 2.384 Probably damaging None Synonymous p16
R87L 2.392 Probably damaging None Synonymous p16
V51D 2.396 Probably damaging None Synonymous p16
P70L 2.453 Probably damaging None Synonymous p16
H98P 2.465 Probably damaging None Synonymous p16
M53T 2.468 Probably damaging None Synonymous p16
R87Pa 2.544 Probably damaging None Synonymous p16
L63P 2.602 Probably damaging None Synonymous p16
P81L 2.75 Probably damaging None Synonymous p16
D74A 2.755 Probably damaging None Synonymous p16
D74V 2.98 Probably damaging None Synonymous p16
P114L 3.181 Probably damaging None Synonymous p16
T79L 1.818 Probably damaging None Synonymous p16
W110X Deleterious None Synonymous p16
aReported germline mutations.
bShown biochemically to have normal MDM2 binding but disrupted nucleolar localization in Rizos et al (2001).
cShown biochemically to have normal MDM2 binding and normal nucleolar localization in Rizos et al (2001).
dShown biochemically to have diminished MDM2 binding but normal nucleolar localization Rizos et al (2001).
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It is theoretically possible that de novo mutations arose in
our cell lines during passaging. Several lines of evidence
argue against the prevalence of this phenomenon. First, the
CDKN2A status of many of our cell lines have been previ-
ously analyzed in other laboratories and the mutations
reproduce despite variations in culture conditions and
genotyping strategies (SK-Mel 63, SK-Mel 131, SK-Mel
119, UACC903, MM455, Mel-Juso, SK-Mel 28 in Walker
et al, 1998; A375, WM164, WM1158 in Ohta et al, 1994;
WM115 in Kumar et al, 1998b). Second, except for the
Pro98Ala mutation in TP53, every mutation that we detect-
ed in either CDKN2A (Ruas and Peters, 1998) or TP53
(http://www-p53.iarc.fr/index.html) has been reported in the
literature in melanomas or other cancers. Third, seven of 13
point mutations in CDKN2A and CDK4 were C ! T UVB
signature mutations, which are unlikely to arise from ran-
dom mutagenesis in our cultured cells. Melanoma cell lines
have led to the discovery of many key melanoma loci to
date including CDKN2A (Kamb et al, 1994), PTEN/MMAC1
(Tsao et al, 1998b), and BRAF (Davies et al, 2002). More-
over, our genetic findings in human melanomas are also
congruous with reported results for primary murine me-
lanomas (Chin et al, 1997; Sharpless et al, 2003) thereby
suggesting more universal cross-species mechanisms. In
summary, we provide evidence that both RB and p53 func-
tionalities are disrupted to a significant extent in melanoma.
Missense CDKN2AExon2 mutations appear to preferentially
target p16, rather than p14ARF, and thus other events are
commonly recruited to inactivate the p53 pathway. The 36
lines that we were able to fully evaluate by genetic and
protein analysis all demonstrated some defect in either RB
or the p53 pathways. The genetic patterns reproduce pro-
files reported in murine melanoma models and therefore
suggest essential mutational milestones in melanomas. We
have also identified several possible associations including
a positive association between CDK4 and TP53 mutations
and negative associations between CDKN2AExon1b deletion
and TP53 mutation and between NRAS and TP53 muta-
tions. The biological implications of these associations
await further reproduction and elucidation.
Materials and Methods
Cell lines and DNA The human melanoma cell lines, culture con-
ditions, uncultured melanoma specimens, and their NRAS and
PTEN/MMAC1 status have been described previously (Tsao et al,
Figure 2
Predicted effects of published CDKN2A exon 2 mutations. Using
PolyPhen, the predicted effects of 117 published exon 2 missense
mutations on p16 and p14ARF are shown. The breakdown by
functional group (i.e., synonymous, benign, possibly damaging,
probably damaging, and deleterious) is shown in (A), while the ratio
of p16/p14ARF PSIC scores (see text) by codon number is shown in
(B).
Figure 3
Multiplex PCR showing homozygous deletions of individual exons in designated cell lines. SK-Mel 28, which harbors a CDK4 mutation, is a
positive control showing retention of CDKN2A exons 1a, 1b, and 2, whereas MM455 is a negative control showing homozygous deletions of these
exons. Arrows define size of individual amplicons derived from each exon.
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2004). Melanoma cell lines in the WM series were gifts from Me-
enherd Herlyn (Wistar Institute, Philadelphia, Pennsylvania); the
MM-RU and MM-LH cell lines were gifts from Dr H. R. Byers
(Boston University Medical Center, Boston, Massachusetts); the K
melanoma lines were from Dr Glen Dranoff (Dana Farber Cancer
Institute, Boston, Massachusetts). Characteristics of these lines
are listed in Table S1.
Multiplex PCR analysis All PCR reactions were carried out in
a 50 mL volume with TaKaRa Taq Polymerase (Fisher Scientific,
Pittsburgh, Pennsylvania) in a final concentration of 10 mM Tris-
HCl (pH 8.3); 50 mM KCl and 1.5 mM MgCl2. Multiplex PCR re-
actions were carried out using a 492 bp fragment of b-tubulin as a
control amplicon (Tub-372F: 50AGA GAGCTGTGACTGCCTG30;
Tub-864R: 50TGAGGTCCGGCACTGTGAG) and exon 1a primers
(5% DMSO; 611C  5 cycles; 461C  20 cycles), exon 2 primers
(10% DMSO; 57.51C  25 cycles) as described in Hussussian et al
(1994) or exon 1b primers (p14ARF-253F: 50ACATGGTGCGCA
GGTTCTTGGT30; p14ARF-473R: 50CCGGACTTTTCGAGGGCC
TTT30; 10% DMSO; 611C  25 cycles). The samples were initially
denatured at 951C 5 min, then amplified for 25 cycles at 601C or
621C. Products were visualized on a 1.5% or 2.0% agarose gel
stained with ethidium bromide.
DNA sequencing Exons 1a and 2 were amplified and sequenced
using primers and conditions described in Hogg et al (2001). Exon
1b was amplified using p14ARF-96F (50GCTCAGGGAAGGCGG
GTGC30) and p14ARF-473R and sequenced using p14ARF-253F
(50ACATGGTGCGCAGGTTCTTGGT30) and p14ARF-320R (50AA-
CCCTCACTCGCGGCGG30). Exons 5–9 of TP53 and exon 2 of
CDK4 were sequenced at Polymorphic DNA Technologies Inc.
(Alameda, California) using primer sequences listed in Table S2.
Western blot analysis Cells were suspended in lysis buffer (50
mM Tris-HCl, pH 7.4, 180 mM NaCl, 1 mM EDTA, 1% Triton -X-100,
1 mM NAV3O4, 10 mM NaF, 10 mg per mL Leupeptin, 1 mM PMSF,
10 mg per mL Aprotinin) and incubated on ice for 20 min. After
sonication for 15 s, equal amounts of total protein lysates with 4%
SDS, 0.1 mg per mL bromophenol blue, and 0.5% 2-mer-
captoethanol were heated at 951C for 5 min and separated with
15% polyacrylamide gels. The proteins in gels were electrophore-
tically transferred to PVDF membranes. Following treatment with
5% non-fat dry milk at room temperature for 1 h, the membranes
were probed with anti-b-tubulin (1:500 dilution; sc-5274; Santa
Cruz Inc.) and anti-p16 (1:500; sc-9968; Santa Cruz Inc.) antibodies
at 41C overnight, followed by appropriate horseradish peroxidase-
conjugated secondary antibodies (Amersham Pharmacia Biotech,
Piscataway, New Jersey). Membranes were washed three times
with 10 mM Tris-buffered saline (pH 7.5) containing 0.1% Tween 20
(TBST) after primary and secondary antibody treatments. Bound
antibodies were visualized by chemiluminescence detection on
autoradiographic film. The images on autoradiographic films were
quantified using the ChemiImager V5.5 Imaging system and soft-
ware. A blank region of each autoradiograph was used to deter-
mine the background signal. All band intensities were then
corrected by subtracting the blank signal. A normalized p16 sig-
nal was obtained by dividing the corrected p16 signal by the cor-
rected b-tubulin signal for each sample; a relative p16 level was
then determined by dividing each sample by the normalized p16
signal from our positive control cell line, SK-Mel 28.
Prediction of mutational effects We utilized the PolyPhen
(http://www.bork.embl-heidelberg.de/PolyPhen/) program to model
and predict effects of missense changes on protein function (Sunyaev
et al, 2000, 2001; Ramensky et al, 2002). Using the program, a Po-
sition-Specific Independent Count (PSIC) score is obtained that
quantifies degree of disruption and a qualitative description of
functional impact (‘‘benign,’’ ‘‘possibly damaging,’’ and ‘‘probably
damaging’’). We did not subject frameshift or nonsense mutations to
the analysis as we assumed that those changes are deleterious for
function.
This work is partially supported by grants through the American Skin
Association, the National Cancer Institute, and the Department of Def-
ense (to H. T.).
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3      1 4  5.3 RB, p53 
3      1 4  5.3 RB, p53 
2      1 3  4.0 RB, p53 
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1      0 1  1.3 RB, p53 
1      0 1  1.3  RB, p53 
1      0 1  1.3 RB, p53 
0      1 1  1.3 RB 
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0      1 1  1.3 RB, p53 
36      39 75 100.0  
  
   Wildtype 
    
Dual RB, p53 70.3% 
  
   Homozygous deletion 
  
loss 
 
  
   Point / frameshift mutation 
* 5 of 6 lines in our study showed some loss of p16 expression on Western blotting
¶ 1 of 2 lines in our study showed some loss of p16 expression on Western blotting
Figure 4
Summary of common CDKN2A genetic lesions in melanoma cell lines.
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